Literature DB >> 23577071

Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy.

Alexander Chi1, Pan Ma, Guishan Fu, Gerry Hobbs, James S Welsh, Nam P Nguyen, Si Young Jang, Jinrong Dai, Jing Jin, Ritsuko Komaki.   

Abstract

BACKGROUND: Helical tomotherapy (HT) and volumetric modulated arc therapy (VMAT) are both advanced techniques of delivering intensity-modulated radiotherapy (IMRT). Here, we conduct a study to compare HT and partial-arc VMAT in their ability to spare organs at risk (OARs) when stereotactic ablative radiotherapy (SABR) is delivered to treat centrally located early stage non-small-cell lung cancer or lung metastases.
METHODS: 12 patients with centrally located lung lesions were randomly chosen. HT, 2 & 8 arc (Smart Arc, Pinnacle v9.0) plans were generated to deliver 70 Gy in 10 fractions to the planning target volume (PTV). Target and OAR dose parameters were compared. Each technique's ability to meet dose constraints was further investigated.
RESULTS: HT and VMAT plans generated essentially equivalent PTV coverage and dose conformality indices, while a trend for improved dose homogeneity by increasing from 2 to 8 arcs was observed with VMAT. Increasing the number of arcs with VMAT also led to some improvement in OAR sparing. After normalizing to OAR dose constraints, HT was found to be superior to 2 or 8-arc VMAT for optimal OAR sparing (meeting all the dose constraints) (p = 0.0004). All dose constraints were met in HT plans. Increasing from 2 to 8 arcs could not help achieve optimal OAR sparing for 4 patients. 2/4 of them had 3 immediately adjacent structures.
CONCLUSION: HT appears to be superior to VMAT in OAR sparing mainly in cases which require conformal dose avoidance of multiple immediately adjacent OARs. For such cases, increasing the number of arcs in VMAT cannot significantly improve OAR sparing.

Entities:  

Mesh:

Year:  2013        PMID: 23577071      PMCID: PMC3618449          DOI: 10.1371/journal.pone.0059729

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Stereotactic ablative radiotherapy (SABR), or stereotactic body radiotherapy (SBRT), has been shown to be an excellent treatment option for early-stage non-small cell lung cancer (NSCLC) and lung metastases when a biologically effective dose (BED) of ≥100 Gy10 is delivered [1]–[4]. However, treatment related death from severe pulmonary toxicities, hemoptysis, or esophagitis, has been reported when various dose fractionation schedules were delivered to treat centrally located lesions [5]–[9]. This happened mainly when a large fractional dose has been delivered, leading to the overdosing of the organs at risk (OARs) adjacent to the tumor target. Therefore, respecting the OAR dose constraints is essential when treating central lesions close to the mediastinal structures to avoid potentially catastrophic consequences [10]. Excellent OAR sparing has been routinely achieved through intensity modulated radiotherapy (IMRT), which generates highly conformal dose avoidance of structures immediately adjacent to the tumor target in various sites [11], [12]. More recently, advanced techniques of IMRT delivery under image guidance, helical tomotherapy (HT) [13] and volumetric modulated arc therapy (VMAT) [14], [15], have been shown to produce more conformal dose distribution, and better OAR sparing when compared to IMRT, or three dimensional conformal radiotherapy (3D-CRT) at various sites [16]–[24]. Thus, HT & VMAT may be more suitable when treating centrally located lung lesions with SABR. Previously, we have demonstrated the feasibility of HT-based SABR for centrally located lung lesions which are very close to critical OARs in the thorax; while VMAT has been shown to be superior to IMRT or 3D-CRT for lung SABR in OAR sparing [22]–[25]. In this dosimetric study multi-arc VMAT and HT and compared directly in their ability to maximally spare immediately adjacent OARs when SABR is delivered to the treat centrally located lung lesions. In addition, potential benefits of increasing the number of arcs for VMAT-based SABR in this setting are explored. In this study, 7 Gy × 10 fractions was investigated because it was associated with an excellent toxicity profile when bulky tumors were treated, and the clinically sound BED achieved with this dose fractionation schedule (119 Gy10) [26].

Methods

Patient and Tumor Characteristics

This study has been approved by the institutional review board (IRB) at the University of Arizona. Since no actual human subjects were involved, no informed consent was needed per IRB. A total of 12 patients with centrally located lesions have been randomly identified. These patients had undergone 3D or intensity-modulated SBRT for stage I-II NSCLC or metastasis to the lung in the department of radiation oncology at the University of Arizona. Central location is defined as the area within 2 cm of the proximal bronchial tree, which includes the lower trachea, carina, mainstem bronchi, and the lobar bronchi. The critical structures are the esophagus, the heart, the spinal cord, major vessels in the mediastinum, and the major airway (lower trachea, carina, mainstem bronchi, and lobar bronchi). The tumor location, size, and its immediately adjacent OARs in each case are listed in Table 1.
Table 1

Patient tumor characteristics.

PatientsLocationPTV volume (cc)Immediately adjacent structuresPTV to structure distance (cm)
1RLL153.68Heart0.15
2LUL70.54Aortic arch1.06
L pulmonary artery0.11
3RUL69.22Heart0.50
SVC0.23
4RML14.04Heart1.22
R middle lobar bronchus0.10
5RUL56.52R mainstem bronchus0.20
R pulmonary artery0.23
6RUL34.91R brachiocephalic artery0.19
7LUL22.79Aorta0.11
8RUL133.64Esophagus1.30
SVC0.26
Trachea1.06
9RUL147.22Heart1.54
R pulmonary artery0.39
10RLL65.76Esophagus0.53
Heart0.13
R pulmonary artery0.22
11LUL24.11Aortic arch0.10
12RML22.69Heart0.23
R middle lobar bronchus0.14
R pulmonary vein0.97

Target Volume Delineation

The gross tumor volume (GTV) was delineated at the lung window level on the treatment planning CT. The clinical target volume (CTV) was defined as the GTV and its immediately adjacent areas which were felt to be at a high risk for microscopic disease extension. The planning target volume (PTV) was the CTV with a 5 mm expansion to account for set up errors and residual tumor motion. Particular attention was paid to avoid overlapping any target volumes with the OARs. In cases for which 4D CT was available, internal target motion was accounted for by 4D CT simulation. The lungs, esophagus, spinal cord, and the heart were contoured for each patient. The major vessels and major airway were contoured only when they are adjacent to the GTV. All the target delineation was performed in the clinical Pinnacle treatment planning system, version 9.0 (Philips Medical Systems, Bothell, WA).

Treatment Planning

Tomotherapy plans were generated in the Tomotherapy Hi-Art planning system using 6 MV photons delivered without a flattening filter. Longitudinal aperture size of 1.05 cm or 2.5 cm, a pitch of 0.3, and a modulation factor of 3 were used. Please refer to our previous study for details [25]. VMAT plans are generated with Smart Arc (SA) using the clinical version 9.0 of Pinnacle to be delivered with 6 MV photons. The machine specification of a Varian linear accelerator with 120 leaf interdigitating MLC is used. VMAT plans were generated with coplanar partial arcs to spare as much contralateral lung as possible. The arc length varied from 150° to 240°. 2-arc and 8-arc plans were created for each case. For 2- arc plans, the delivery time was constrained to 3 minutes. Delivery time was not limited for 8-arc plans. Continuous gantry motion, dose-rate variation, and MLC motion were approximated by optimizing individual beams at 4° gantry angle increments. The machine configuration was based on the “Recommended Smart Arc Physics Parameters” from Philips (Andover, MA. Recommended Smart Arc Physics Parameters. Philips Application Note 2009-03 Rev. A). Except that the “Max MU” limitation, which is 999 by default, has been changed to 5999. All SABR plans prescribed 70 Gy delivered in 10 daily fractions to the PTV with heterogeneity corrections. They were optimized to have at least 95% of the PTV receiving 100% of the prescription dose with collapsed-cone convolution (CCC) algorithm for both HT and SA. Please refer to our previous study for details on the dose constraints used [27]. PTV coverage took precedence over OAR sparing in all plans. All treatment plans were designed under the same set of planning guidelines agreed upon among the authors with similar levels of emphasis placed on the PTV and the OARs. HT planning was conducted at the University of Arizona, and VMAT planning was conducted at the Cancer Hospital & Institute at Peking Union Medical College. In addition, all the plans were designed to deliver a dose that is used in daily clinical practice.

Plan Comparison

Various lung dose parameters and the maximum dose (Dmax) to specific OARs generated in HT and VMAT plans were compared to assess their ability for OAR sparing. For the PTV, the dose covering 95% of the PTV (D95), the % PTV receiving ≥70 Gy (V70 Gy), the mean dose (Dmean) & Dmax, the homogeneity index (HI), and the conformation number (CN) were generated and compared between different techniques. The HI and CN are previously defined [28], and are described below: D2 and D98 represent the doses to 2% and 98% of the PTV, Dp is the prescription dose. For the CN, the first portion (1st parentheses) is an assessment of target volume coverage by 95% of the prescription dose; and the second part (2nd parentheses) is an assessment of normal tissue sparing (the volume of normal tissue receiving ≥95% of the prescribed dose). The CN values between 0 and 1 with 1 representing the ideal conformity (Fig. 1a). In other situations that may be encountered in SABR delivery, a less-than-ideal CN is achieved when the target is partially covered by the desired dose with proportionately increased irradiation of the healthy tissue (Fig. 1b); or increased volume of healthy tissue may be irradiated within the limit of the allowed dose constraints due to the need to adequately cover the target volume and to spare a critical structure that is in its proximity (Fig. 1c).
Figure 1

Illustration of the possible scenarios of dose conformity described by the conformation number (CN).

The shade represents the target volume, the dotted line represents the desired isodose, the small solid in c) represent a critical structure that is immediately adjacent to the target. a). the ideal dose conformation with CN = 1. b). Less than optimal coverage of the target volume. c). In situations where the target is next to a critical structure, both adequate dose coverage of the target and the sparing of the critical structure are desired. As a result, more healthy tissue is irradiated in the context of the healthy tissue dose constraint as shown. The CN will be <1 is both b) and c).

Illustration of the possible scenarios of dose conformity described by the conformation number (CN).

The shade represents the target volume, the dotted line represents the desired isodose, the small solid in c) represent a critical structure that is immediately adjacent to the target. a). the ideal dose conformation with CN = 1. b). Less than optimal coverage of the target volume. c). In situations where the target is next to a critical structure, both adequate dose coverage of the target and the sparing of the critical structure are desired. As a result, more healthy tissue is irradiated in the context of the healthy tissue dose constraint as shown. The CN will be <1 is both b) and c). The differences in tumor characteristics, such as tumor size and the distance between the PTV & its immediately adjacent structures, were sought between the group of patients for whom optimal PTV coverage and OAR sparing was achieved (Group 1) and those whose plans were suboptimal (Group 2). Group 1 included both HT and VMAT plans (2 and/or 8 arc plans). Group 2 included patients for whom either the HT or both VMAT plans could not successfully spare ≥1 immediately adjacent OAR if adequate PTV coverage was maintained.

Statistical Analysis

Dosimetric parameters generated in the HT, 2-arc, and 8-arc plans were compared through a randomized complete block ANOVA. After the dose parameters for the OARs and the target volumes were obtained from the HT and the VMAT plans, they were normalized to the OAR dose constraints listed in Table 2. Selected OAR dose parameters from the HT, and VMAT plans were compared using multifactorial ANOVA while controlling for differences between patients and various OARs. In the assessment of each treatment technique’s influence on OAR sparing, multiple logistic regression was then performed on these selected normalized parameters. In analyzing the differences in tumor characteristics between groups 1 & 2, one-way ANOVA was used. Statistical significance was defined by a p value <0.05. All analyses were performed using JMP-Pro/v9.0.2 (SAS Institute Inc., Cary, NC).
Table 2

Comparison of PTV dose coverage parameters generated through helical tomotherapy, VMAT with 2 arcs, and 8 arcs with absolute doses illustrated in mean ± standard deviation.

VMAT P value
HT2 Arcs8 ArcsHT vs. 2 ArcsHT vs. 8 Arcs2 Arcs vs. 8 Arcs
PTV dose coverage parameters
D95 (Gy)70.61±0.6170.00±0.0070.00±0.000.00030.00030.99
V70 Gy (%)96.15±1.2295.00±0.0095.00±0.000.00060.00060.99
Dmean (Gy)74.03±1.7476.12±1.5374.99±1.690.0020.110.06
Dmax (Gy)81.98±3.6682.76±2.7780.76±2.390.460.260.07
CN0.64±0.060.61±0.110.63±0.110.170.730.29
HI19.23±10.9521.45±6.6617.83±5.750.240.450.06

Results

HT and VMAT SABR plans were generated for all 12 patients to meet the PTV dose coverage criteria. The PTV, lung, and other OARs’ dose parameters generated with each treatment approach are summarized in Tables 2, 3, and -4, respectively, with any two different techniques compared directly.
Table 3

Comparison of lung dosimetric parameters generated through helical tomotherapy, VMAT with 2 arcs, and 8 arcs with absolute doses illustrated in mean ± standard deviation.

VMAT P value
HT2 Arcs8 ArcsHT vs. 2 ArcsHT vs. 8 Arcs2 Arcs vs. 8 Arcs
Total lung
MLD (Gy)6.48±2.337.23±3.476.50±2.530.240.970.25
V5 21.16±8.0322.89±10.1522.31±9.250.230.420.68
V10 15.88±5.4815.16±6.1814.62±5.780.380.130.51
V20 10.49±4.1610.27±4.129.94±3.860.820.570.73
Ipsilateral lung
MLD (Gy)10.72±3.6712.70±4.9812.03±4.500.030.150.45
V5 34.10±13.2938.22±14.0937.64±13.660.030.060.75
V10 28.35±11.1130.19±10.9027.93±10.360.420.150.32
V20 19.50±8.8121.42±8.0620.78±7.680.360.540.76
Contralateral lung
MLD (Gy)1.62±0.751.64±0.761.60±0.670.900.950.85
V5 7.04±6.278.76±7.108.10±5.700.360.570.72
V10 2.11±2.881.11±1.110.98±1.160.060.040.79
V20 0.27±0.420.04±0.090.05±0.070.040.040.98

HT vs. 2-arc VMAT

For the PTV, D95 and V70 Gy were significantly higher in the HT plans (Table 2). HT also generated significantly lower Dmean (p = 0.002). No significant difference in the Dmax, CN, and HI was found. For the total lung (volume of both lungs – GTV), no significant differences in the mean lung dose (MLD), V5, V10, and V20 was observed (Table 3). The ipsilateral MLD and V5 were significantly lower in HT plans (p = 0.03, 0.03, respectively). On the contrary, 2-arc VMAT achieved lower V20 in the contralateral lung (p = 0.04). HT generated significantly lower Dmax for the heart and the major vessels (p = 0.02, 0.01, respectively), while a trend toward lower Dmax for the major airway was observed (p = 0.07) (Table 4). However, lower Dmax to the spinal cord was found in VMAT plans (p = 0.03).
Table 4

Comparison of the maximum dose other organs at risk (OARs) generated through helical tomotherapy, VMAT with 2 arcs, and 8 arcs with absolute doses illustrated in mean ± standard deviation.

VMAT P value
HT2 Arcs8 ArcsHT vs. 2 ArcsHT vs. 8 Arcs2 Arcs vs. 8 Arcs
Dmax for other OARs (Gy)
Spinal cord18.84±7.4414.18±8.5713.65±8.200.030.020.79
Esophagus22.72±13.0622.71±13.5222.28±11.840.990.620.62
Heart23.08±22.8329.77±26.7029.66±26.540.020.030.97
Major airway34.10±15.0237.97±17.3737.30±17.090.070.120.74
Major vessels46.30±3.2050.91±6.5149.03±5.350.010.090.24

HT vs. 8-arc VMAT

Significantly higher D95 and V70 Gy for the PTV for HT was the only observed difference in the target dose indices (Table 2). Total-lung dose parameters were equivalent, while the contralateral V10 & V20 was significantly lower in VMAT plans (p = 0.04, 0.04, respectively) (Table 3). For other OARs, HT achieved lower Dmax to the heart, while VMAT achieved lower Dmax to the spinal cord (p = 0.03, 0.02, respectively) (Table 4).

2-arc vs. 8-arc VMAT

For the PTV, a trend toward significance for lower Dmean, Dmax, and HI were observed (p = 0.06, 0.07, 0.06, respectively) (Table 2). No significant difference between the 2 & 8-arc plans was found in any of the OAR parameters (Tables 3 & 4).

Dmax for Adjacent OARs and MLD, V20 for the Total Lung ((MLDtotal, V20, total) after Normalizing to the Dose Constraints Used

No statistically significant difference between the three different techniques was observed in the normalized dose parameters when patient and OAR differences were controlled (Fig. 2). However, the treatment technique was found to be a statistically significant factor influencing OAR sparing (meeting dose constraints), favoring HT for all OARs as an aggregate, when compared with VMAT techniques (p = 0.0004); specifically affecting MLDtotal (p = 0.0219), and Dmax to the heart (p = 0.0219) & the major vessels (p = 0.0033). OAR sparing was successfully achieved in all HT plans. However, OAR overdosing was found in 2 &/or 8-arc plans in patients 3, 9, 10, 11, 12 (Fig. 2). Increasing from 2 to 8 arcs decreased the esophageal Dmax for patient 10, and the MLDtotal for patient 3 to below the dose threshold (Fig. 2a, f). The same did not occur for the heart, the major airway, the major vessels, and the MLDtotal for patients 9, 10, 11, and 12 (Fig. 2b, c, d, and f). However, increasing from 2 to 8 arcs decreased the Dmax to the major vessels and the spinal cord in many cases (Fig. 2d, e).
Figure 2

Comparison of dose parameters to the organs at risk.

Organs at risk: a) Esophagus, b) heart, c) major airway, d) major vessels, e) spinal cord, f) and g) mean lung dose (MLD) and V20 for the total lung, after normalized to the absolute dose constraints between helical tomotherapy (Tomo), 2-arc, and 8-arc VMAT plans.

Comparison of dose parameters to the organs at risk.

Organs at risk: a) Esophagus, b) heart, c) major airway, d) major vessels, e) spinal cord, f) and g) mean lung dose (MLD) and V20 for the total lung, after normalized to the absolute dose constraints between helical tomotherapy (Tomo), 2-arc, and 8-arc VMAT plans.

Tumor Characteristics for Patients for Whom Neither VMAT Plans Achieved Optimal OAR Sparing

The tumor characteristics for group 2 (patients 9–12) were compared with those for group 1 (patients 1–8). Given the small sample size for each group, no significant difference was found in PTV diameter, volume, and distances to the closest and furthest immediately adjacent OARs (Table 5). 2/4 cases in group 2 had 3 immediately adjacent structures (50%), while only 2 such cases were found in group 1 (25%). The median PTV to its closest OAR distance was also slightly shorter in group 2 when compared with group 1 (0.13 cm vs. 0.17 cm).
Table 5

Tumor characteristics for groups of patients for whom optimal OAR sparing and tumor volume dose coverage can be achieved with HT or any one form of VMAT (Group 1) and those patients among whom optimal OAR sparing cannot be achieved if optimal tumor volume coverage is desired with VMAT (Group 2).

PTV diameter (cm)PTV volume (cc)Number of immediately adjacent normal structuresShortest distanceto the PTV (cm)Longest distance to thePTV (cm)
Group 16.05±1.9069.42±50.461.88±0.840.17±0.060.61±0.50
Group 25.94±1.7465.07±58.612.25±0.960.19±0.130.79±0.62

Discussion

Although higher D95 and V70 Gy were found in HT plans, this is mostly due to the differences in how target coverage parameters were executed in the treatment planning systems (TPS) under comparison. No significant difference in dose conformality was found between HT and VMAT plans. However, increasing from 2 to 8 arcs led to a trend toward lower PTV Dmean, Dmax, and HI (Table 2). Thus, suggesting a potential for improving dose homogeneity by increasing the number of arcs when treating targets in areas of complex geometry with VMAT. This finding is consistent with what has been previously observed by Guckenberger et al [29]. Poor CN has been found with all three different techniques (Table 2). The CN achieved in our VMAT plans was lower than what has been reported in the literature [22]. This may be partially due to the degree of complexity in OAR sparing in close vicinity to the target; which is especially true when multiple OARs are immediately adjacent to the PTV, making it extremely difficult to conform the dose to the PTV in all directions. In these cases, less conformity is observed due to increased dose to the healthy tissue that has the least demanding dose constraint in the context of each specific case as previously shown in Fig. 1c. This is also illustrated in Figure 3, where the desired isodose can be seen to include additional normal lung tissue due to the sparing of immediately adjacent normal structures. In the same illustration, increased dose homogeneity from the 8-Arc plan is also shown as the 77 Gy isodose is significantly diminished when compared with the 2-Arc plan. Thus, supporting that dose homogeneity may be improved by increasing the number of arcs.
Figure 3

Illustration of a comparison of the 2 and 8 Arc plans demonstrating that the shape of the isodose covering the PTV is largely dependent on the immediately adjacent critical structures (yellow and blue) that need to be spared in one patient.

As a result, slightly increased volume of the normal lung tissue is included in the high dose volume lateral to the PTV (blue shade) away from the central structures. Also shown here is that when comparing to the 2 Arc plan, the high dose region included by the 77 Gy isodose in the 8 Arc plan is greatly diminished, demonstrating increased homogeneity.

Illustration of a comparison of the 2 and 8 Arc plans demonstrating that the shape of the isodose covering the PTV is largely dependent on the immediately adjacent critical structures (yellow and blue) that need to be spared in one patient.

As a result, slightly increased volume of the normal lung tissue is included in the high dose volume lateral to the PTV (blue shade) away from the central structures. Also shown here is that when comparing to the 2 Arc plan, the high dose region included by the 77 Gy isodose in the 8 Arc plan is greatly diminished, demonstrating increased homogeneity. Lung dose parameters in HT and VMAT plans are shown in Table 3. VMAT plans demonstrated significantly lower contralateral lung dose parameters when compared to HT plans (Table 3). This can possibly be explained by the difference in the degree of the arc generated in 2 different TPS, which is partial arc for VMAT and full arc for HT. Due to the already very low values of the contralateral lung dose parameters, VMAT’s potentially improved contralateral lung sparing may not be of any clinical significance. For the ipsilateral lung, potential factors of clinical relevance, the V5, and MLD, were significantly lower in HT plans when compared to 2-arc plans [30]. However, this significance was lost when HT and 8-arc plans were compared. Similar to what was observed for the ipsilateral lung, HT has demonstrated significantly lower Dmax to the major vessels than 2-arc VMAT. However, this significance was lost when HT was compared to 8-arc VMAT. Although no significant difference was observed in any OAR dose parameters between 2 & 8 arcs VMAT plans, these observations again suggest that increasing from 2 to 8 arcs for VMAT-based SABR may have a potential for improving conformal dose avoidance in areas of complex geometry. With patient and OAR differences controlled, no difference in a series of normalized dosimetric parameters was found between the three techniques (Fig. 2). However, the technique used was found to be a significant factor influencing the ability to meet OAR dose constraints favoring HT over VMAT. Optimal OAR sparing was achieved in all cases by HT, but only the first 8 cases for VMAT (Fig. 2). Increasing from 2 to 8 arcs helped to meet the dose constraints for certain structures for patients 3 & 10 (Fig. 2 a, f), and decreased Dmax for the spinal cord and the major vessels in many cases (Fig. 2 d, e). This did not lead to meeting the dose constraints for all immediately adjacent OARs for patients 9–12, among whom increased number of immediately adjacent structures and short distance between PTV and the closest OAR were common. No statistically significant difference in tumor characteristics was found between patients 9–12 and patients 1–8 due to the small number of patients studied (Table 5). However, our findings suggest that HT may be more appropriate in cases which demand conformal dose avoidance of multiple structures (≥2) that are very close to the PTV in the delivery of SABR for centrally located lung lesions, even though increasing the number of arcs in VMAT may improve OAR sparing in certain situations. Our findings are corroborated in a study comparing HT and VMAT in delivering conventionally fractionated radiotherapy in several body sites by Rong et al, which demonstrated improved target dose homogeneity and lower doses to more critical structures in the HT plans [28]. This is mainly due to the increased freedom of intensity modulation created by delivering image-guided IMRT under synchronous gantry rotation and couch motion with HT [13], [25]. Although shown to be more capable of OAR sparing in setting of lung SABR for central lesions, HT is associated with much longer fractional treatment delivery time of >40 minutes for each case, mainly attributing to the complexity of intensity modulation required. Due to this fact, the exact treatment time for the HT plans was not recorded. On the other hand, 2 & 8 arc VMAT had average fractional treatment delivery times of only 180 & 331 seconds, respectively. Thus, VMAT remains to be more desirable for targets in areas of relatively less complex geometry. The prolonged treatment time associated with HT can be potentially improved by implementing the dynamic jaw and dynamic couch feature [31]. At the current time, this remains a problem for HT-based SABR mainly because of its associated increase in intrafractional motion, which can be critical when treating central lesions with SABR. As a result, proper respiratory motion management and careful body immobilization are essential [32], [33]. In our experience, 4D CT simulation to account for tumor motion in various locations remains the most straight forward approach for respiratory motion management for HT clinically. Furthermore, treatment efficiency can be improved by dividing the fractional dose into two consecutive fractions (7 Gy delivered in 2 consecutive fractions, 3.5 Gy/fraction) [34]. The dose delivery & calculation accuracy have been commented elsewhere, which were found to be adequate for both VMAT and HT [28]. In a study by Takahashi et al, the CCC algorithm closely approximated the Monte Carlo algorithm in the dose calculation specific for lung SBRT [35]. This warrants the validity of SABR dose calculation for both HT and VMAT, which is also critical in the setting of centrally located lesions closely surrounded by multiple critical OARs. Early clinical reports on treating mostly peripheral lesions with HT-based and VMAT-based SABR have been promising [34], [36]. A prospective clinical study investigating how to best apply these advanced techniques in the treatment of central lung lesions with SABR will be conducted in the near future. Due the virtual nature of this dosimetric study, no further quality assurance is conducted. However, treatment planning accuracy for VMAT and HT are implied from studies conducted in the past (25, 37). But it will be done as part of a prospective study in the future.

Conclusion

In delivering SABR or SBRT for centrally located lung lesions, HT appears to be superior to VMAT in OAR sparing mainly for targets with multiple immediately adjacent structures. Although increasing arc number cannot achieve the aim of sparing all the OARS in cases associated with complex geometry, it may help lowering the doses to them. However, VMAT may be preferred over HT in cases of simpler geometry due to much shorter treatment delivery time.
  37 in total

1.  Volumetric modulated arc therapy for nasopharyngeal carcinoma: a dosimetric comparison with TomoTherapy and step-and-shoot IMRT.

Authors:  Szu-Huai Lu; Jason Chia-Hsien Cheng; Sung-Hsin Kuo; Jason Jeun-Shenn Lee; Liang-Hsin Chen; Jian-Kuen Wu; Yu-Hsuan Chen; Wan-Yu Chen; Shu-Yu Wen; Fok-Ching Chong; Chien-Jang Wu; Chun-Wei Wang
Journal:  Radiother Oncol       Date:  2012-01-09       Impact factor: 6.280

2.  Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.

Authors:  Tingyi Xia; Hongqi Li; Qingxuan Sun; Yingjie Wang; Naibin Fan; Yong Yu; Ping Li; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-09       Impact factor: 7.038

Review 3.  Tomotherapy and other innovative IMRT delivery systems.

Authors:  John D Fenwick; Wolfgang A Tomé; Emilie T Soisson; Minesh P Mehta; T Rock Mackie
Journal:  Semin Radiat Oncol       Date:  2006-10       Impact factor: 5.934

4.  Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.

Authors:  Hiroshi Onishi; Hiroki Shirato; Yasushi Nagata; Masahiro Hiraoka; Masaharu Fujino; Kotaro Gomi; Yuzuru Niibe; Katsuyuki Karasawa; Kazushige Hayakawa; Yoshihiro Takai; Tomoki Kimura; Atsuya Takeda; Atsushi Ouchi; Masato Hareyama; Masaki Kokubo; Ryusuke Hara; Jun Itami; Kazunari Yamada; Tsutomu Araki
Journal:  J Thorac Oncol       Date:  2007-07       Impact factor: 15.609

5.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

6.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.

Authors:  Robert Timmerman; Ronald McGarry; Constantin Yiannoutsos; Lech Papiez; Kathy Tudor; Jill DeLuca; Marvene Ewing; Ramzi Abdulrahman; Colleen DesRosiers; Mark Williams; James Fletcher
Journal:  J Clin Oncol       Date:  2006-10-20       Impact factor: 44.544

Review 7.  Intensity-modulated radiation therapy in head and neck cancers: an update.

Authors:  Nancy Lee; Dev R Puri; Angel I Blanco; K S Clifford Chao
Journal:  Head Neck       Date:  2007-04       Impact factor: 3.147

8.  The management of respiratory motion in radiation oncology report of AAPM Task Group 76.

Authors:  Paul J Keall; Gig S Mageras; James M Balter; Richard S Emery; Kenneth M Forster; Steve B Jiang; Jeffrey M Kapatoes; Daniel A Low; Martin J Murphy; Brad R Murray; Chester R Ramsey; Marcel B Van Herk; S Sastry Vedam; John W Wong; Ellen Yorke
Journal:  Med Phys       Date:  2006-10       Impact factor: 4.071

9.  Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.

Authors:  Rikiya Onimaru; Hiroki Shirato; Shinichi Shimizu; Kei Kitamura; Bo Xu; Shin-ichi Fukumoto; Ta-Chen Chang; Katsuhisa Fujita; Masataka Oita; Kazuo Miyasaka; Masaharu Nishimura; Hirotoshi Dosaka-Akita
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

10.  Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution.

Authors:  Yi-Jen Chen; An Liu; Chunhui Han; Peter T Tsai; Timothy E Schultheiss; Richard D Pezner; Nilesh Vora; Dean Lim; Stephen Shibata; Kemp H Kernstine; Jeffrey Y C Wong
Journal:  Med Dosim       Date:  2007       Impact factor: 1.482

View more
  9 in total

1.  Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC.

Authors:  S Arcangeli; L Agolli; L Portalone; M R Migliorino; M G Lopergolo; A Monaco; J Dognini; M C Pressello; S Bracci; V Donato
Journal:  Br J Radiol       Date:  2015-02-03       Impact factor: 3.039

2.  Feasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT.

Authors:  Jian He; Yan Huang; Yixing Chen; Shiming Shi; Luxi Ye; Yong Hu; Jianying Zhang; Zhaochong Zeng
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

Review 3.  The radiation techniques of tomotherapy & intensity-modulated radiation therapy applied to lung cancer.

Authors:  Zhengfei Zhu; Xiaolong Fu
Journal:  Transl Lung Cancer Res       Date:  2015-06

4.  Dosimetric evaluation of compensator intensity modulation-based stereotactic body radiotherapy for Stage I non-small-cell lung cancer.

Authors:  Y Tajima; H Nakayama; T Itonaga; S Shiraishi; M Okubo; R Mikami; S Sugahara; K Tokuuye
Journal:  Br J Radiol       Date:  2015-05-21       Impact factor: 3.039

5.  Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience.

Authors:  Vanessa Figlia; Rosario Mazzola; Francesco Cuccia; Filippo Alongi; Gianluca Mortellaro; Daniela Cespuglio; Teresa Cucchiara; Giuseppina Iacoviello; Vito Valenti; Massimo Molino; Francesco Verderame; Domenica Matranga; Antonio Lo Casto; Giuseppe Ferrera
Journal:  Radiol Med       Date:  2018-02-17       Impact factor: 3.469

6.  Comparison of outcomes of stereotactic body radiation therapy delivered with three different technologies to the lung.

Authors:  Sameera S Kumar; Logan Hall; Xingzhe Li; Laura Downes; Andrew Shearer; Brent J Shelton; Samuel Gerring; Ronald C McGarry
Journal:  J Radiosurg SBRT       Date:  2018

Review 7.  Complications from Stereotactic Body Radiotherapy for Lung Cancer.

Authors:  Kylie H Kang; Christian C Okoye; Ravi B Patel; Shankar Siva; Tithi Biswas; Rodney J Ellis; Min Yao; Mitchell Machtay; Simon S Lo
Journal:  Cancers (Basel)       Date:  2015-06-15       Impact factor: 6.639

8.  Comparison of Two RapidArc Delivery Strategies in Stereotactic Body Radiotherapy of Peripheral Lung Cancer with Flattening Filter Free Beams.

Authors:  Bao-Tian Huang; Jia-Yang Lu; Pei-Xian Lin; Jian-Zhou Chen; Yu Kuang; Chuang-Zhen Chen
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

9.  A treatment-planning comparison of three beam arrangement strategies for stereotactic body radiation therapy for centrally located lung tumors using volumetric-modulated arc therapy.

Authors:  Kentaro Ishii; Wataru Okada; Ryo Ogino; Kazuki Kubo; Shun Kishimoto; Ryuta Nakahara; Ryu Kawamorita; Yoshie Ishii; Takuhito Tada; Toshifumi Nakajima
Journal:  J Radiat Res       Date:  2016-03-06       Impact factor: 2.724

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.